The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J. Erstad, Andrew M. Tager, Yujin Hoshida, Bryan C. Fuchs

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Original languageEnglish (US)
Article numbere1311827
JournalMolecular and Cellular Oncology
Volume4
Issue number3
DOIs
StatePublished - May 4 2017
Externally publishedYes

Keywords

  • ATX
  • chemoprevention
  • cirrhosis
  • fibrosis
  • HCC
  • hepatocellular carcinoma
  • LPA
  • LPAR1
  • NASH
  • non-alcoholic steatohepatitis

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer'. Together they form a unique fingerprint.

  • Cite this